Business Wire Feed
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Data from PAnTHa, the global Phase I first-in-human, dose-escalation study were presented during the more...
Median Technologies to present at the TD Cowen 46th Annual Health Care Conference
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a more...
CORRECTING and REPLACING Children’s Hospital Los Angeles Launches 11th Annual Make March Matter® Fundraising Campaign
More than 90 Southern California businesses will rally individuals during March in support of pediatric health and research at CHLALOS ANGELES--(BUSINESS WIRE)--The seventh paragraph should read: The following businesses also earned the distinction of being in more...
CFG Health Launches CareLink™ — A Fully Integrated, 24/7 Telehealth Platform for Correctional Health Care
Proprietary Technology Expands Access, Enhances Safety, and Redefines How Care Is Delivered Inside Correctional FacilitiesMOUNT LAUREL, N.J.--(BUSINESS WIRE)--CFG Health today announced the launch of CFG CareLink™, a proprietary, in-house telehealth platform that represents the next more...
Acupath Laboratories, Inc. Partners with Azer Scientific to Install the First AzerView Digital Pathology Scanner in the United States
PLAINVIEW, N.Y.--(BUSINESS WIRE)--Three pathology and healthcare technology leaders today announced a partnership that has resulted in the installation of the first LH510 Digital Pathology scanner in the United States, marking a significant milestone in the more...
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status Results from the final analysis of the Phase 3 KEYNOTE-B96 more...
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancersAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global more...
Paw Prosper Acquires Blue-9 Pet Products, Expanding Integrated Conditioning and Fitness Solutions for Pet Professionals and Parents
DENVER--(BUSINESS WIRE)--Paw Prosper, an animal health and wellness platform dedicated to helping pets stay healthy, recover quickly, and age gracefully, today announced the acquisition of Blue-9 Pet Products, a leader in innovative tools for behaviour more...
Free Live Webinar Wednesday — Behind The Olympics with America’s Most Decorated Cross Country Skier Jessie Diggins
Jessie will discuss the 2026 Winter Olympics, eating disorder recovery, and her inspiring new documentary Threshold now on Peacock. Registration is free and limited to 1000 people.SAINT PAUL, Minn.--(BUSINESS WIRE)--The Emily Program, a national leader more...
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease at surgery The results, combined with the more...
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
First and only immunotherapy plus antibody-drug conjugate regimen, used perioperatively, to significantly extend survival for these patients KEYNOTE-B15 is the sixth study demonstrating overall survival with a KEYTRUDA-based regimen in an earlier-stage cancer Late-breaking results more...
Omdia: Xiaomi Reclaims Wearable Band Crown for the First Time Since 2020
LONDON--(BUSINESS WIRE)--#Omdia--Global wearable device shipments climbed past 200 million units in 2025, growing 6% year on year according to Omdia. Xiaomi has reclaimed the top spot for the first time since 2020, capturing an 18% more...
Four Feinstein Institutes Scientists Honored as National Academy of Inventors Senior Members
Lior Brimberg, Jared M. Huston, Stavros Zanos and Theodoros Zanos recognized for impactful innovations and patented technologiesMANHASSET, N.Y.--(BUSINESS WIRE)--In recognition of their impact on society through the successful production, patenting and commercialization of groundbreaking technologies, more...
Medsynaptic to Showcase Medsynapse PACS and Orthopedic Imaging Solutions at AAOS 2026 in New Orleans
NEW ORLEANS--(BUSINESS WIRE)--#3DSolutions--Medsynaptic, a global provider of enterprise imaging and PACS solutions, today announced its participation in the AAOS Annual Meeting to be held in New Orleans from 3rd March to 5th March. Medsynaptic will more...
OSSTEC Appoints Dr. Nick Pachuda to Board and Establishes US Operations Ahead of US Market Entry
LONDON--(BUSINESS WIRE)--OSSTEC, a UK-based orthopaedics company developing next-generation cementless knee replacement technology, today announced updates supporting its US market entry: The appointment of Dr. Nick Pachuda to its Board of Directors and the establishment of more...
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 JERSEY more...
Three-Year Data Reinforce Revi® System as the Most Clinically Validated Implantable Tibial Neuromodulation Therapy for Urgency Urinary Incontinence
New data confirm Revi’s unmatched durability, 95% patient satisfaction, and excellent safety over three years, setting a new standard in Implantable Tibial NeuromodulationSALT LAKE CITY--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in Implantable Tibial Neuromodulation (ITNM) more...
AdvoCare® Launches Limited-Time BodyLean25® Protein Birthday Cake Flavor
Celebrating Company’s 33rd BirthdayRICHARDSON, Texas--(BUSINESS WIRE)--#AdvoCareRehydrate--AdvoCare International, LLC is celebrating its 33rd Birthday with a festive new Limited-Time Offering: BodyLean25® protein in Birthday Cake Flavor. This celebratory twist on one of AdvoCare’s most beloved performance more...
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
Aiming to Develop New Gut Microbiota Test Items and a Personalized Food Recommendation AlgorithmTOKYO & YAMAGATA, Japan--(BUSINESS WIRE)--Cowellnex Co., Ltd. (Cowellnex)—jointly established by Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Kyowa Kirin Co., Ltd. (Kyowa more...
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of more...
Summit Therapeutics to Present at Upcoming Investor Conferences
MIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate more...
AHF Sues FL Health Dept. to Block Emergency Rule Cutting HIV Drug Access for Thousands
Florida’s Department of Health DOH resorted to procedural trickery this week, adopting a new emergency rule to cut off funding and access to lifesaving HIV medications for thousands of Floridians on March 1, says AHFFORT more...
Weave to Present at Raymond James 47th Annual Institutional Investors Conference
LEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a leading vertical SaaS platform that delivers AI-powered patient engagement and payment solutions for small and medium-sized healthcare practices, today announced it will participate in the 47th Raymond James Institutional more...
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA
15th QA & Dosimetry Symposium convenes medical physics and radiation therapy community in Rome Two days of sessions span diverse topics from 24 clinical practitioners and thought leaders Event introduces new Daily QA™ 4 Pro more...
HCA Healthcare, Inc. to Present at March Conferences
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences: March 3, 2026 at 10:30am ET at the TD Cowen Health Care Conference March 4, 2026 at 9:50am ET more...